EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response

Katie Ridge iD, Rizwan Ahmad iD, Barry Moran iD, Cliona O'Farrelly iD, Jean Dunne iD, Conor M Finlay iD, Alan D Irvine iD, Niall Conlon

Clinical & Experimental Allergy · 2025

DOI: 10.1111/cea.70100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von Katie Ridge und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCARE Centre, Clinical and Diagnostic Immunology, St. James's Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Precision Medicine, Chronic Urticaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Health Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic spontaneous urticaria (CSU) is a skin disorder characterised by recurrent hives and swellings that has a profound effect upon quality of life. Current guidelines for the management of CSU outline sequential use of standard dosing nonsedating H1 antihistamines, fourfold dose antihistamines and the anti‐IgE monoclonal antibody omalizumab. A proportion of patients will have partial response or no response to omalizumab despite uptitration of dose. Evidence suggests that nonresponders may represent a specific endotype of Type IIb autoimmune CSU and respond better to ciclosporin, a fourth line off‐licence treatment. Accurate and timely classification of CSU by endotype may enable personalised medicine for patients. Current attempts to classify CSU are based on distinct autoallergic and autoimmune pathways towards mast cell activation; Type I autoallergic urticaria as evidenced by IgE autoantibodies initiating FcεR1 crosslinking and Type IIb autoimmune urticaria as evidenced by IgG autoantibodies initiating FcεR1 crosslinking. However, recent data have demonstrated that the distinction between CSU endotypes is more nuanced, with overlap between categories whereby patients with Type IIb autoimmune CSU have been found to have coexistent IgE autoantibodies. A cohort of patients do not meet criteria for either endotype. Furthermore, there is recognition that laboratory parameters currently used to stratify patients are not widely available, hampering their practical use. This review seeks to summarise data on biomarkers associated with treatment response in CSU. While previous literature has focussed upon treatment response to antihistamines, our emphasis is on predicting treatment response to third and fourth‐line treatments, with further reference to emerging treatments that do not yet form part of guidelines for management of CSU. Understanding factors that influence clinical response to all agents is particularly important as treatment options for CSU rapidly expand. In the following sections, we will evaluate the biochemical and clinical parameters that have been explored in these patients as well as their potential utility in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineChronic UrticariaHumansOmalizumabImmunoglobulin EAutoantibodiesReceptors, IgEAnti-Allergic AgentsTreatment Outcome

Stichwörter der Autor:innen

biomarkerschronic spontaneous urticariadermatologyflow cytometrymast cellstranslational immunology

Substanzen

OmalizumabImmunoglobulin EAutoantibodiesReceptors, IgEAnti-Allergic Agents

Autor:innen und Institutionen

  • UCARE Centre, Clinical and Diagnostic Immunology, St. James's Hospital, Dublin, Ireland.
  • School of Medicine, Trinity College Dublin, Dublin, Ireland.
  • School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, Trinity Kidney Centre, Dublin, Ireland.

ORCID-Profile: Katie Ridge, Rizwan Ahmad, Barry Moran, Cliona O'Farrelly, Jean Dunne, Conor M Finlay, Alan D Irvine

Förderung

  • Wellcome Trust
  • Health Research Board

Zitieren

APA

Ridge, K., Ahmad, R., Moran, B., O'Farrelly, C., Dunne, J., Finlay, C. M., Irvine, A. D., & Conlon, N. (2025). Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70100

Vancouver

Ridge K, Ahmad R, Moran B, O'Farrelly C, Dunne J, Finlay CM, et al. Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70100

BibTeX
@article{Ridge2025,
  author = {Ridge, Katie and Ahmad, Rizwan and Moran, Barry and O'Farrelly, Cliona and Dunne, Jean and Finlay, Conor M and Irvine, Alan D and Conlon, Niall},
  title = {Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  doi = {10.1111/cea.70100}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche